These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 15204161)

  • 1. Testing of antifungal combinations against yeasts and dermatophytes.
    Harman S; Ashbee HR; Evans EG
    J Dermatolog Treat; 2004 Apr; 15(2):104-7. PubMed ID: 15204161
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro antifungal susceptibility patterns of dermatophyte strains causing tinea unguium.
    Sarifakioglu E; Seçkin D; Demirbilek M; Can F
    Clin Exp Dermatol; 2007 Nov; 32(6):675-9. PubMed ID: 17714532
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro susceptibility testing of ciclopirox, terbinafine, ketoconazole and itraconazole against dermatophytes and nondermatophytes, and in vitro evaluation of combination antifungal activity.
    Gupta AK; Kohli Y
    Br J Dermatol; 2003 Aug; 149(2):296-305. PubMed ID: 12932235
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro activity of voriconazole against dermatophytes, Scopulariopsis brevicaulis and other opportunistic fungi as agents of onychomycosis.
    Carrillo-Muñoz AJ; Giusiano G; Guarro J; Quindós G; Guardia C; del Valle O; Rodríguez V; Estivill D; Cárdenes CD
    Int J Antimicrob Agents; 2007 Aug; 30(2):157-61. PubMed ID: 17555945
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antifungal susceptibility patterns of yeasts and filamentous fungi isolated from nail infection.
    Ataides FS; Chaul MH; El Essal FE; Costa CR; Souza LK; Fernandes OF; Silva MR
    J Eur Acad Dermatol Venereol; 2012 Dec; 26(12):1479-85. PubMed ID: 22049990
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Terbinafine susceptibility patterns for onychomycosis-causative dermatophytes and Scopulariopsis brevicaulis.
    Carrillo-Muñoz AJ; Giusiano G; Cárdenes D; Hernández-Molina JM; Eraso E; Quindós G; Guardia C; del Valle O; Tur-Tur C; Guarro J
    Int J Antimicrob Agents; 2008 Jun; 31(6):540-3. PubMed ID: 18367383
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro activity of the lipopeptide derivative (Pal-Lys-Lys-NH), alone and in combination with antifungal agents, against clinical isolates of dermatophytes.
    Simonetti O; Arzeni D; Ganzetti G; Silvestri C; Cirioni O; Gabrielli E; Castelletti S; Kamysz W; Kamysz E; Scalise G; Offidani A; Barchiesi F
    Br J Dermatol; 2009 Aug; 161(2):249-52. PubMed ID: 19438437
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of antifungal agents in onychomycoses.
    Debruyne D; Coquerel A
    Clin Pharmacokinet; 2001; 40(6):441-72. PubMed ID: 11475469
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of the antimicrobial susceptibility of fungi responsible for onychomycosis in Spain.
    Zalacain A; Obrador C; Martinez JP; Viñas M; Vinuesa T
    Med Mycol; 2011 Jul; 49(5):495-9. PubMed ID: 21142899
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro antifungal oral drug and drug-combination activity against onychomycosis causative dermatophytes.
    Santos DA; Hamdan JS
    Med Mycol; 2006 Jun; 44(4):357-62. PubMed ID: 16772230
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A multicentre, randomized, controlled study of the efficacy, safety and cost-effectiveness of a combination therapy with amorolfine nail lacquer and oral terbinafine compared with oral terbinafine alone for the treatment of onychomycosis with matrix involvement.
    Baran R; Sigurgeirsson B; de Berker D; Kaufmann R; Lecha M; Faergemann J; Kerrouche N; Sidou F
    Br J Dermatol; 2007 Jul; 157(1):149-57. PubMed ID: 17553051
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low
    Abastabar M; Haghani I; Shokohi T; Hedayati MT; Aghili SR; Jedi A; Dadashi S; Shabanzadeh S; Hosseini T; Aslani N; Meis JF; Badali H
    Antimicrob Agents Chemother; 2018 Dec; 62(12):. PubMed ID: 30224524
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The prevalence, aetiological agents and therapy of onychomycosis in patients with psoriasis: a prospective controlled trial.
    Kaçar N; Ergin S; Ergin C; Erdogan BS; Kaleli I
    Clin Exp Dermatol; 2007 Jan; 32(1):1-5. PubMed ID: 16824053
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro evaluation of combination antifungal activity against Fusarium species isolated from ocular tissues of keratomycosis patients.
    Li L; Wang Z; Li R; Luo S; Sun X
    Am J Ophthalmol; 2008 Nov; 146(5):724-8. PubMed ID: 18707669
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fusarium spp. as agents of onychomycosis in immunocompetent hosts.
    Guilhermetti E; Takahachi G; Shinobu CS; Svidzinski TI
    Int J Dermatol; 2007 Aug; 46(8):822-6. PubMed ID: 17651164
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular typing and antifungal susceptibility of Trichophyton rubrum isolates from patients with onychomycosis pre- and post-treatment.
    de Assis Santos D; de Carvalho Araújo RA; Kohler LM; Machado-Pinto J; Hamdan JS; Cisalpino PS
    Int J Antimicrob Agents; 2007 May; 29(5):563-9. PubMed ID: 17331707
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Determination of susceptibility/resistance to antifungal drugs of Trichophyton mentagrophytes isolates by a macrodilution method.
    Barros ME; Hamdan JS
    Can J Microbiol; 2005 Nov; 51(11):983-7. PubMed ID: 16333338
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Short communication: In vitro activity of amphotericin B with fluconazole or voriconazole combinations against Candida albicans isolates].
    Oz Y; Akşit F; Kiraz N; Kiremitçi A
    Mikrobiyol Bul; 2008 Jan; 42(1):149-55. PubMed ID: 18444574
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New insights into the effect of amorolfine nail lacquer.
    Flagothier C; Piérard-Franchimont C; Piérard GE
    Mycoses; 2005 Mar; 48(2):91-4. PubMed ID: 15743424
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination of oral terbinafine and topical ciclopirox compared to oral terbinafine for the treatment of onychomycosis.
    Avner S; Nir N; Henri T
    J Dermatolog Treat; 2005; 16(5-6):327-30. PubMed ID: 16428154
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.